- sulfasalazine was developed over 50 years ago to specifically treat RA;
- more recently it has been found to be efficacious for psoriatic arthritis;
- typical adult dose is 1 gm per day, but may be increased to 2 gm per day;
- most common adverse side effect with sulfasalazine is gastrointestinal intolerance;
- hematologic toxicity, including hemolytic anemia, folate deficiency, thrombocytopenia, leukopenia, and rarely, aplastic anemia, may occur;
- rarely, reversible oligospermia, fever, rash, exfoliative dermatitis, and pneumonitis may rarely develop
Sulphasalazine in the management of psoriatic arthritis.
Comparison of sulfasalazine and placebo in the treatment of psoriatic arthritis. A Department of Veterans Affairs Cooperative Study.
Psoriatic arthritis: a quantitative overview of therapeutic options: the Psoriatic Arthritis Meta Analysis Study Group.
Sulphasalazine in psoriatic arthritis: a randomized, multicentre, placebo controled study.